The compliance of physicians to current guidelines for asymptomatic microhaematuria is limited and the evidence supporting asymptomatic microhaematuria as an effective screening tool for the early detection of bladder cancer is weak. Medical or surgical treatment is indicated in 13–35% of patients with asymptomatic microhaematuria, albeit mostly for benign conditions, which are more commonly the cause. The high prevalence of asymptomatic microhaematuria in the general population means that this condition poses a considerable challenge to the health-care system.
References
Davis, R. et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J. Urol. 188 (Suppl.), 2473–2481 (2012).
Schmitz-Drager, B. J. et al. Microhematuria assessment an IBCN consensus — based upon a critical review of current guidelines. Urol. Oncol. 34, 437–451 (2016).
Burger, M. et al. Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846–854 (2013).
Richards, K. A., Ham, S., Cohn, J. A. & Steinberg, G. D. Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: implications for sex disparities. Int. J. Urol. 23, 42–47 (2016).
Cohn, J. A. et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer 120, 555–561 (2014).
Brehmer, M. Imaging for microscopic hematuria. Curr. Opin. Urol. 12, 155–159 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Steinberg, G. Assessing the conundrum of microscopic haematuria. Nat Rev Urol 13, 700–701 (2016). https://doi.org/10.1038/nrurol.2016.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.229
- Springer Nature Limited
This article is cited by
-
Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis
Nature Communications (2021)